Evidence map›Paper›PMID 27992432›Full record

ArticlePloS one2016

A Gastric Glycoform of MUC5AC Is a Biomarker of Mucinous Cysts of the Pancreas.

Jessica Sinha, Zheng Cao, Jianliang Dai, Huiyuan Tang, Katie Partyka, Galen Hostetter, Diane M Simeone, Ziding Feng, Peter J Allen, Randall E Brand and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Clinical and Molecular Attributes and Evaluation of Pancreatic Cystic Neoplasm.Biochimica et biophysica acta. Reviews on cancer · 2023
    Review
  8. Pancreatic cancer in 2021: What you need to know to win.World journal of gastroenterology · 2021
    Review
  9. Observational
  10. Review
  11. Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Article
  12. Molecular Diagnosis of Cystic Neoplasms of the Pancreas: a Review.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020
    Review
  13. Molecular Diagnostics and Testing for Pancreatic Cysts.Current treatment options in gastroenterology · 2020
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Jessica SinhaVan Andel Research Institute, Grand Rapids, MI, United States of America.
Zheng CaoVan Andel Research Institute, Grand Rapids, MI, United States of America.
Jianliang DaiMD Anderson Cancer Center, Houston, TX, United States of America.
Huiyuan TangVan Andel Research Institute, Grand Rapids, MI, United States of America.
Katie PartykaVan Andel Research Institute, Grand Rapids, MI, United States of America.
Galen HostetterVan Andel Research Institute, Grand Rapids, MI, United States of America.
Diane M SimeoneUniversity of Michigan School of Medicine, Ann Arbor, MI, United States of America.
Ziding FengMD Anderson Cancer Center, Houston, TX, United States of America.
Peter J AllenMemorial Sloan Kettering Cancer Center, New York, NY, United States of America.
Randall E BrandUniversity of Pittsburgh Medical Center, Pittsburgh, PA, United States of America.
Brian B HaabVan Andel Research Institute, Grand Rapids, MI, United States of America.
Van Andel Institute · USThe University of Texas MD Anderson Cancer Center · USMemorial Sloan Kettering Cancer Center · USUniversity of Michigan–Ann Arbor · USUniversity of Pittsburgh Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Validation of biomarkers for risk prediction and early diagnosis of Pancreatic AdenocarcinomaU01CA200466 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Surinder K. Batra, Randall Brand · 2016 to 2026
$11.3M
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan BiomarkersU01CA152653 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI ALLEN, PETER J, BRAND, RANDALL · 2010 to 2021
$5.8M
Targeted Glycomics and Affinity Reagents for Cancer Biomarker DevelopmentU01CA168896 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI HAAB, BRIAN B. · 2012 to 2016
$2.3M
NCI NIH HHS P30 CA008748NCI NIH HHS U01 CA152653NCI NIH HHS U01 CA168896NCI NIH HHS U01 CA200466
6 · The paper itself

Abstract

Molecular indicators to specify the risk posed by a pancreatic cyst would benefit patients. Previously we showed that most cancer-precursor cysts, termed mucinous cysts, produce abnormal glycoforms of the proteins MUC5AC and endorepellin. Here we sought to validate the glycoforms as a biomarker of mucinous cysts and to specify the oligosaccharide linkages that characterize MUC5AC. We hypothesized that mucinous cysts secrete MUC5AC displaying terminal N-acetylglucosamine (GlcNAc) in either alpha or beta linkage. We used antibody-lectin sandwich assays to detect glycoforms of MUC5AC and endorepellin in cyst fluid samples from three independent cohorts of 49, 32, and 66 patients, and we used monoclonal antibodies to test for terminal, alpha-linked GlcNAc and the enzyme that produces it. A biomarker panel comprising the previously-identified glycoforms of MUC5AC and endorepellin gave 96%, 96%, and 87% accuracy for identifying mucinous cysts in the three cohorts with an average sensitivity of 92% and an average specificity of 94%. Glycan analysis showed that MUC5AC produced by a subset of mucinous cysts displays terminal alpha-GlcNAc, a motif expressed in stomach glands. The alpha-linked glycoform of MUC5AC was unique to intraductal papillary mucinous neoplasms (IPMN), whereas terminal beta-linked GlcNAc was increased in both IPMNs and mucinous cystic neoplasms (MCN). The enzyme that synthesizes alpha-GlcNAc, A4GNT, was expressed in the epithelia of mucinous cysts that expressed alpha-GlcNAc, especially in regions with high-grade dysplasia. Thus IPMNs secrete a gastric glycoform of MUC5AC that displays terminal alpha-GlcNAc, and the combined alpha-GlcNAc and beta-GlcNAc glycoforms form an accurate biomarker of mucinous cysts.

Indexed as

AcetylglucosamineAdenocarcinoma, MucinousBiomarkersCarcinoma, Pancreatic DuctalCarcinoma, PapillaryCohort StudiesGlycosylationHeparan Sulfate ProteoglycansHumansMucin 5ACN-AcetylglucosaminyltransferasesPancreatic CystPancreatic NeoplasmsPeptide FragmentsAcetylglucosamineBiomarkersHeparan Sulfate ProteoglycansMUC5AC protein, humanMucin 5ACN-AcetylglucosaminyltransferasesPeptide Fragmentsperlecan

Identifiers

PMID27992432
PMCPMC5167232
OpenAlexW2563436770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.